Go Pro

Genelux (GNLX) 10K Form and Latest SEC Filings 2026

Genelux logo
$2.96 -0.07 (-2.31%)
Closing price 07/13/2026 04:00 PM Eastern
Extended Trading
$2.96 0.00 (-0.03%)
As of 04:55 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Genelux SEC Filings & Recent Activity

Genelux (NASDAQ:GNLX) has submitted 270+ documents to the U.S. Securities and Exchange Commission (SEC) since 2022. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Genelux's financial statements. The most recent filing was a Form 4 submitted on July 2, 2026.

Form 4
GENELUX Corp Reports Ownership Change on Jul. 2, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Genelux Files Current Report on Jun. 22, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Genelux Files Annual Report on Mar. 19, 2026

The 10-K contains Genelux's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Genelux SEC Filing History

Browse Genelux's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
07/02/2026 3:35 PM
Genelux (1231457) Issuer
Smither John W (1559583) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/01/2026 5:16 PM
Genelux (1231457) Subject
Smither John W (1559583) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/22/2026 3:45 PM
Genelux (1231457) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/18/2026 6:05 PM
Genelux (1231457) Issuer
Smither John W (1559583) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2026 6:05 PM
Genelux (1231457) Issuer
Yu Yong (1937482) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2026 6:05 PM
Genelux (1231457) Issuer
Mirabelli Mary (1937525) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2026 6:05 PM
Genelux (1231457) Issuer
Thomas John (1939103) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2026 6:05 PM
Genelux (1231457) Issuer
Zindrick Thomas (1937573) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2026 6:05 PM
Genelux (1231457) Issuer
Tyree James L (1324991) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2026 6:05 PM
Cappello Joseph (1939198) Reporting
Genelux (1231457) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2026 6:05 PM
Genelux (1231457) Issuer
Groen Eric (1918630) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2026 6:05 PM
Genelux (1231457) Issuer
Pulisic Matthew (2054836) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2026 7:35 PM
Genelux (1231457) Issuer
Smalling Ralph (1983288) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/02/2026 7:35 PM
Genelux (1231457) Issuer
Thomas John (1939103) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/01/2026 3:32 PM
Genelux (1231457) Subject
Thomas John (1939103) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/12/2026 7:30 PM
Genelux (1231457) Issuer
Smalling Ralph (1983288) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 7:30 PM
Genelux (1231457) Issuer
Zindrick Thomas (1937573) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 7:30 PM
Cappello Joseph (1939198) Reporting
Genelux (1231457) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 7:30 PM
Genelux (1231457) Issuer
Yu Yong (1937482) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/29/2026 7:10 AM
Genelux (1231457) Filer
Form ARS
04/29/2026 7:00 AM
Genelux (1231457) Filer
Form DEF 14A
04/29/2026 7:05 AM
Genelux (1231457) Filer
Form DEFA14A
03/26/2026 4:00 PM
Genelux (1231457) Issuer
Zindrick Thomas (1937573) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/26/2026 4:00 PM
Genelux (1231457) Issuer
Yu Yong (1937482) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/26/2026 4:00 PM
Cappello Joseph (1939198) Reporting
Genelux (1231457) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/26/2026 4:00 PM
Genelux (1231457) Issuer
Smalling Ralph (1983288) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/19/2026 4:27 PM
Genelux (1231457) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/19/2026 4:30 PM
Genelux (1231457) Filer
Form 424B5
03/19/2026 3:05 PM
Genelux (1231457) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/03/2026 7:05 PM
Genelux (1231457) Issuer
Thomas John (1939103) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/02/2026 3:32 PM
Genelux (1231457) Subject
Thomas John (1939103) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/17/2026 4:58 PM
Genelux (1231457) Subject
Szalay Aladar (1937513) Filed by
Form SCHEDULE 13G/A
01/08/2026 4:05 PM
Genelux (1231457) Filer
Form 424B5
01/08/2026 4:09 PM
Genelux (1231457) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/07/2026 4:30 PM
Genelux (1231457) Issuer
Litten Jason (1909400) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/07/2026 4:32 PM
Genelux (1231457) Issuer
Litten Jason (1909400) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2026 3:48 PM
Genelux (1231457) Filer
Form 424B5
01/05/2026 7:15 AM
Genelux (1231457) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/02/2026 3:10 PM
Genelux (1231457) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/11/2025 7:49 PM
Cappello Joseph (1939198) Reporting
Genelux (1231457) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2025 7:50 PM
Genelux (1231457) Issuer
Zindrick Thomas (1937573) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
Under $1 while the market panics (Ad)

The new deadline for crypto’s best bill, the Clarity Act, is August 7th. That's the Senate's final session day before summer recess. The bill needs 60 votes, seven Democrats crossing the aisle. If it happens, trillions in institutional capital finally gets the legal rulebook it's been waiting years for. And our analysts have identified one specific altcoin they believe was built for exactly this moment. Not for retail hype… for the kind of regulated, institutional finance the CLARITY Act unlocks.tc pixel

Get our #1 pick before the CLARITY Act passes.
12/11/2025 7:50 PM
Genelux (1231457) Issuer
Yu Yong (1937482) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/09/2025 7:00 PM
Genelux (1231457) Issuer
Smalling Ralph (1983288) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/02/2025 6:00 PM
Genelux (1231457) Issuer
Thomas John (1939103) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2025 3:34 PM
Genelux (1231457) Subject
Thomas John (1939103) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/14/2025 5:44 PM
ARMISTICE CAPITAL, LLC (1601086) Filed by
Genelux (1231457) Subject
Form SCHEDULE 13G
09/03/2025 3:15 PM
Cappello Joseph (1939198) Reporting
Genelux (1231457) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/03/2025 3:15 PM
Genelux (1231457) Issuer
Smalling Ralph (1983288) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/03/2025 3:15 PM
Genelux (1231457) Issuer
Yu Yong (1937482) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/03/2025 3:15 PM
Genelux (1231457) Issuer
Zindrick Thomas (1937573) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/03/2025 3:05 PM
Genelux (1231457) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/29/2025 3:30 PM
Cappello Joseph (1939198) Reporting
Genelux (1231457) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/29/2025 3:30 PM
Genelux (1231457) Issuer
Tyree James L (1324991) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/29/2025 3:30 PM
Genelux (1231457) Issuer
Mirabelli Mary (1937525) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/29/2025 3:30 PM
Genelux (1231457) Issuer
Yu Yong (1937482) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/29/2025 3:30 PM
Genelux (1231457) Issuer
Smither John W (1559583) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/29/2025 3:30 PM
Genelux (1231457) Issuer
Smalling Ralph (1983288) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/29/2025 3:30 PM
Genelux (1231457) Issuer
Zindrick Thomas (1937573) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/29/2025 3:30 PM
Genelux (1231457) Issuer
Thomas John (1939103) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/07/2025 3:46 PM
Genelux (1231457) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
07/25/2025 4:00 PM
Genelux (1231457) Subject
Szalay Aladar (1937513) Filed by
Form SCHEDULE 13G/A
(Data available from 1/1/2016 forward)

Genelux SEC Filings - Frequently Asked Questions

Genelux (GNLX) has submitted 270+ filings to the SEC since 2022. You can browse the complete history or filter by form type using the tools above.

Genelux's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Genelux's financial statements page.

The most recent filing was a Form 4 submitted on July 2, 2026. This was an insider ownership change filed by 4 - GENELUX Corp (0001231457) (Issuer).

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:GNLX) was last updated on 7/14/2026 by MarketBeat.com Staff.
From Our Partners